A case of lymphoma-associated haemophagocytic syndrome in advanced-stage mycosis fungoides

2020 ◽  
Vol 30 (5) ◽  
pp. 606-608
Author(s):  
Tasuku Kitano ◽  
Masaharu Nakao ◽  
Kyosuke Oishi ◽  
Shintaro Maeda ◽  
Takashi Matsushita ◽  
...  
Keyword(s):  
Mycosis Fungoides ◽  
Advanced Stage ◽  
Haemophagocytic Syndrome

Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome

2018 ◽  
Vol 20 (4) ◽  
Author(s):  
Louise Photiou ◽  
Carrie van der Weyden ◽  
Christopher McCormack ◽  
H. Miles Prince
Keyword(s):  
Mycosis Fungoides ◽  
Systemic Treatment ◽  
Treatment Options ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Advanced Stage

scholarly journals Durable Control of Mycosis Fungoides after Sepsis: “Coley’s Toxin?” Case Report and Review of the Literature

2019 ◽  
Vol 2019 ◽  
pp. 1-4
Author(s):  
Benjamin Heyman ◽  
Chris R. Kelsey ◽  
Anne Beaven
Keyword(s):  
Staphylococcus Aureus ◽  
Immune Response ◽  
Mycosis Fungoides ◽  
Cell Lymphoma ◽  
Single Agent ◽  
Severe Infection ◽  
Advanced Stage ◽  
Cutaneous T Cell Lymphoma ◽  
Review Of The Literature ◽  
Durable Response

Mycosis fungoides, along with Sezary syndrome, is the most common subtype of cutaneous T-cell lymphoma. In this report, we present a patient with advanced-stage mycosis fungoides, who after successful treatment of methicillin-resistantStaphylococcus aureusbacteremia had prolonged disease control off systemic therapy. While this may have been due to single-agent gemcitabine, which can result in long remission, we hypothesize that our patient’s durable response was in part due to the immune response elicited after treatment of her severe infection.

Safety and outcome of allogeneic stem cell transplantation in mycosis fungoides and Sezary syndrome: A seven-year tertiary center analysis.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e20038-e20038
Author(s):  
Selami Kocak Toprak ◽  
Guldane Cengiz Seval ◽  
Erden Atilla ◽  
Sinem Civriz Bozdag ◽  
Meltem Kurt Yuksel ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Mycosis Fungoides ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Advanced Stage ◽  
Hematopoietic Stem ◽  
Tertiary Center ◽  
Unrelated Donors

e20038 Background: Allogeneic hematopoietic stem cell transplantation (AHSCT) is a promising strategy for treatment of advanced-stage mycosis fungoides/Sezary syndrome (MF/SS). In this study, we retrospectively analyzed the outcomes of AHSCT for MF/SS and found that MF/SS appears to be susceptible to graft versus leukemia (GVL) effects. Methods: We studied outcomes in a consecutive series of 14 patients with MM/SS who underwent AHSCT between January 2012-November 2019 at our center. Treatment response was evaluated according to the Consensus WHO criteria for MF/SS. Results: The median age of patients 51.5 years (range: 28-68 years). Eight patients had MF and six patients had SS. Nine of those 14 patients had large cell transformation. All patients had advanced disease (stages IIB: n = 1, IIIA: n = 2, IIIB: n = 6, IVA1: n = 2 and IVB = 3). The median interval from disease onset to AHSCT was 3.7 years (range: 10.5 mos-11.3 years). All of the patients received at least three lines of treatments prior to AHSCT. Four patients achieved CR (3 are alive and still in CR) and all the other patients had progressive disease (PD) at the time of AHSCT. Graft source was peripheral blood stem cell in all patients. Six patients underwent transplantation from 9/10 HLA-matched unrelated donors and eight patients from HLA-identical sibling donors. Most of the patients (12/14) received RIC regimen (Flu-Cy-TBI) and ATG-Fresenius also added the protocol in AHSCT from unrelated donors. Five patients had stage 2-4 cutaneous acute GVHD and chronic GVHD developed in four patients (mild: n = 1, moderate: n = 2, severe: n = 1). Six patients who underwent transplantation at PD attained CR after AHSCT however relapse occurred in four patients at a median of four months (range: 3-10 months) after HSCT. At the time of data collection, nine patients have deceased; three were due to early TRM, three were underlying disease, two had aspergillus infection and one had nocardia infection. Two patients were alive with disease being treated by the Brentixumab vedotin, gemcitabine and DLI. With a median follow up period of 8.7 months after AHSCT, the estimated 1-year OS and PFS was 40.4%±5% and 35.4%±3.9%, respectively. Conclusions: AHSCT is an effective treatment option for advanced-stage MF/SS. Further studies are warranted to improve the outcome after AHSCT.

scholarly journals Increased Twist expression in advanced stage of mycosis fungoides and Sézary syndrome

2012 ◽  
Vol 39 (5) ◽  
pp. 500-507 ◽  
Author(s):  
Meghali Goswami ◽  
Madeleine Duvic ◽  
Alexis Dougherty ◽  
Xiao Ni
Keyword(s):  
Mycosis Fungoides ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Advanced Stage ◽  
Twist Expression

Advanced-Stage Mycosis Fungoides and Sézary Syndrome: Survival and Response to Treatment

2015 ◽  
Vol 15 (6) ◽  
pp. e105-e112 ◽  
Author(s):  
Silvia Alberti-Violetti ◽  
Rakhshandra Talpur ◽  
Megan Schlichte ◽  
Dawen Sui ◽  
Madeleine Duvic
Keyword(s):  
Mycosis Fungoides ◽  
Response To Treatment ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Advanced Stage

scholarly journals Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model

2015 ◽  
Vol 33 (32) ◽  
pp. 3766-3773 ◽  
Author(s):  
Julia J. Scarisbrick ◽  
H. Miles Prince ◽  
Maarten H. Vermeer ◽  
Pietro Quaglino ◽  
Steven Horwitz ◽  
...  
Keyword(s):  
Lactate Dehydrogenase ◽  
Mycosis Fungoides ◽  
Prognostic Markers ◽  
Cell Transformation ◽  
Survival Rates ◽  
Prognostic Index ◽  
Stage Iv ◽  
Large Cell ◽  
Advanced Stage ◽  
Large Cell Transformation

Purpose Advanced-stage mycosis fungoides (MF; stage IIB to IV) and Sézary syndrome (SS) are aggressive lymphomas with a median survival of 1 to 5 years. Clinical management is stage based; however, there is wide range of outcome within stages. Published prognostic studies in MF/SS have been single-center trials. Because of the rarity of MF/SS, only a large collaboration would power a study to identify independent prognostic markers. Patients and Methods Literature review identified the following 10 candidate markers: stage, age, sex, cutaneous histologic features of folliculotropism, CD30 positivity, proliferation index, large-cell transformation, WBC/lymphocyte count, serum lactate dehydrogenase, and identical T-cell clone in blood and skin. Data were collected at specialist centers on patients diagnosed with advanced-stage MF/SS from 2007. Each parameter recorded at diagnosis was tested against overall survival (OS). Results Staging data on 1,275 patients with advanced MF/SS from 29 international sites were included for survival analysis. The median OS was 63 months, with 2- and 5-year survival rates of 77% and 52%, respectively. The median OS for patients with stage IIB disease was 68 months, but patients diagnosed with stage III disease had slightly improved survival compared with patients with stage IIB, although patients diagnosed with stage IV disease had significantly worse survival (48 months for stage IVA and 33 months for stage IVB). Of the 10 variables tested, four (stage IV, age > 60 years, large-cell transformation, and increased lactate dehydrogenase) were independent prognostic markers for a worse survival. Combining these four factors in a prognostic index model identified the following three risk groups across stages with significantly different 5-year survival rates: low risk (68%), intermediate risk (44%), and high risk (28%). Conclusion To our knowledge, this study includes the largest cohort of patients with advanced-stage MF/SS and identifies markers with independent prognostic value, which, used together in a prognostic index, may be useful to stratify advanced-stage patients.

Sign in / Sign up

Export Citation Format

Share Document